SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc., (NASDAQ:ILMN - News) today announced that LIFE & BRAIN is the first company in Germany to become an Illumina CSPro® (certified service provider). Illumina CSPro is a collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. LIFE & BRAIN offers its customers whole-genome genotyping services using Illumina’s Infinium® Assay. The Infinium HD (High-Density) product line provides researchers with the ability to perform large-scale interrogation of the human genome to cost-effectively fast forward their research and identify genetic variants linked to disease.
“Our mission is to delineate the molecular pathogenesis of common diseases and to develop specific diagnostic and therapeutic tools,” said Sven Cichon, Ph.D., Head of the Molecular Genetics Laboratory at LIFE & BRAIN. “By becoming an Illumina CSPro, we are demonstrating our commitment to our customers by offering them access to the highest quality genetic analysis services.”
Illumina CSPro participants undergo a rigorous two-phase certification process that includes minimum data generation, data certification, and an on-site audit of the facility and processes. To find out more about Illumina’s CSPro program, please visit www.illumina.com/cspro.
“Interest in the Illumina CSPro program continues to grow with almost 20 academic and commercial technology providers already certified or in the process of certification. Now that LIFE & BRAIN is a partner, we are excited to work with them to make it easier for researchers in Germany to access the power of Illumina’s genetic analysis technologies,” said Karen Possemato, Director of Corporate Marketing at Illumina.
About LIFE & BRAIN
Combining expertise in genomics, transgenics, cellomics, and cognitive neuroscience, LIFE & BRAIN represents a center of excellence in the field of translational biomedicine (www.lifeandbrain.com). Representing one of LIFE & BRAIN’s R&D platforms, the Department of Genomics focuses on the identification of genetic factors that are involved in the development of human complex diseases. The GENOMICS platform can build on ample expertise at the local neuroscience center, in particular for the identification of susceptibility genes associated with complex genetic diseases affecting the central nervous system, such as manic depression, schizophrenia, and certain forms of epilepsy. The analysis of the human genome along with SNP genotyping and related technologies provide enormous opportunities to achieve the goals envisaged by the Department of Genomics.
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina’s ability (i) to integrate effectively our recent acquisition of Solexa, Inc., (ii) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (iii) to manufacture robust microarrays and Oligator® oligonucleotides, (iv) to integrate and scale our VeraCode technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.
Public Relations Manager
Peter J. Fromen
Sr. Director, Investor Relations
Source: Illumina, Inc.